HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fineman, J. R. Search for Related Content PubMed Articles by Fineman, J. R. Related Collections Related Article

Ann Thorac Surg 2000;69:1913
© 2000 The Society of Thoracic Surgeons

---

Invited commentary

Invited commentary

^a Cardiovascular Research Institute, Department of Pediatrics, University of California, San Francisco, 505 Pamassus Ave, Moffit 680, San Francisco, CA 94143-0106, USA

e-mail: jfineman@ped.card.ucsf.edu

Numerous animal and human studies clearly demonstrate that inhaled nitric oxide (NO) is a potent, selective, and endothelium-independent pulmonary vasodilator [1]. For these reasons, its use has been advocated in the care of children and adults with increased pulmonary vascular resistance secondary to heart disease. In the management of children with congenital heart disease, several indications have been advocated. These include its use in the pre-operative assessment of the vasodilatory capacity of the pulmonary circulation, its use in the post-operative assessment of reactive vs. anatomic pulmonary . . . [Full Text of this Article]

Related Article

Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease

Ronald W. Day, John A. Hawkins, Edwin C. McGough, Kevin L. Crezeé, and Garth S. Orsmond
Ann. Thorac. Surg. 2000 69: 1907-1912. [Abstract] [Full Text] [PDF]